Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Talphera (NASDAQ:TLPH) to a hold rating in a research report sent to investors on Saturday.

Several other analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research note on Friday, July 17th. Zacks Research upgraded Talphera to a “hold” rating in a research report on Monday, June 8th. Westpark Capital began coverage on shares of Talphera in a report on Thursday, April 30th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, HC Wainwright started coverage on shares of Talphera in a research report on Friday, June 5th. They set a “buy” rating and a $3.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.00.

Talphera Trading Down 1.4%

NASDAQ:TLPH opened at $1.41 on Friday. Talphera has a 12 month low of $0.40 and a 12 month high of $1.57. The firm has a fifty day simple moving average of $1.15 and a 200-day simple moving average of $0.95. The company has a market capitalization of $73.18 million, a P/E ratio of -4.55 and a beta of 0.69.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Equities analysts forecast that Talphera will post -0.26 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLPH. Group One Trading LLC raised its position in shares of Talphera by 3,224.0% in the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares during the period. Virtu Financial LLC acquired a new stake in shares of Talphera during the 3rd quarter valued at about $29,000. Persistent Asset Partners Ltd purchased a new position in shares of Talphera in the 4th quarter valued at about $42,000. Mariner LLC increased its stake in shares of Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares in the last quarter. Finally, Dauntless Investment Group LLC purchased a new position in shares of Talphera in the 3rd quarter valued at about $89,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.